TREA

97417038 - SYLENTIS

Follow

Information

  • Trademark
  • 97417038
  • Serial Number
    97417038
  • Filing Date
    May 18, 2022
    2 years ago
  • Transaction Date
    August 01, 2024
    7 months ago
  • Status Date
    August 01, 2024
    7 months ago
  • Location Date
    November 06, 2023
    a year ago
  • Status Code
    602
  • Current Location
    TMO LAW OFFICE 128 - EXAMINING ATTORNEY ASSIGNED
    Employee Name
    WATSON, BRIDGET ANNE
  • Attorney Name
    Elizabeth Lee D'Amore
    Law Office Assigned Location Code
    O10
  • Owners
Information
Mark Drawing Code
4
Mark Identification
SYLENTIS
Case File Statements
  • GS0051: Ophthalmologic preparations for the treatment of ocular disorders or diseases; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of ocular disorders or diseases; collyrium; ophthalmic preparations; medicated gels, creams and washing solutions for eye use; medicated eye drops; medicated eye lotions; medicated eye sprays; medicated eye ointments for treating dry eye, ocular pain and conjunctivitis; all the foregoing excluding those comprising isotopes or compounds labelled with stable isotopes
  • GS0421: Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Development of pharmaceutical preparations and medicines; Pharmaceutical product evaluation; Research in the field of pharmaceuticals; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy; Development of pharmaceutical preparations and medicines for the treatment of eye diseases and conditions; Development of pharmaceutical preparations and medicines for the treatment of ocular disorders or diseases; Testing, inspection, research, or development of pharmaceutical preparations for the treatment of eye diseases and conditions; Testing, inspection, research, or development of pharmaceutical preparations for the treatment of ocular disorders or diseases; all the foregoing excluding isotope labelling and diagnostics
Case File Event Statements
  • 3/7/2023 - 2 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 5/21/2022 - 2 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 5/24/2022 - 2 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 3/20/2023 - a year ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 3/20/2023 - a year ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 3/20/2023 - a year ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 6/20/2023 - a year ago
    7 - APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Type: XELR
  • 6/20/2023 - a year ago
    8 - APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Type: XELG
  • 9/19/2023 - a year ago
    9 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 9/19/2023 - a year ago
    10 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 9/20/2023 - a year ago
    11 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 11/6/2023 - a year ago
    13 - FINAL REFUSAL E-MAILED Type: GNFR
  • 11/6/2023 - a year ago
    12 - FINAL REFUSAL WRITTEN Type: CNFR
  • 11/6/2023 - a year ago
    14 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 8/1/2024 - 7 months ago
    15 - ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Type: ABN2
  • 8/1/2024 - 7 months ago
    16 - ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Type: MAB2